Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

My Approach to Investing in CAR-T Drug Development: Cryoport (CYRX, Buy, $5.67)); Kite (KITE, Neutral, $104.34); Juno (JUNO, Neutral, $27.87), Novartis, (NVS, No opinion, $84.85)

Report Highlights

The pending approval of Novartis’ Car-T drug tisagenlecleucel is the beginning of a new era of drugs based…
Read more…

SmithOnStocks Top Stock Picks for 2017, January 3, 2017

Purpose of this Report

I last summarized my stock recommendations in a September 12, 2016 report. There has been little change…
Read more…

Updating My Investment Thinking on Kite (KITE, Neutral, $47.63) and Juno (JUNO, Neutrl, 17.86) in the Aftermath of the ASH Meeting

Introduction to Report

I was closely watching the Amercian Society of Hematology (ASH) meeting held during December 3 to 6 for…
Read more…

My Current Investment Thinking on Kite (KITE, Neutral, $50.02) and Juno (JUNO, Neutral, $20.14) and the CAR-T Space as a Whole

Key Investment Conclusions

I believe that Juno will cease development of JCAR-015 and turn to JCAR-017 as its lead CAR-T…
Read more…

A Non-Consensus, More Balanced Look at the CAR-T Development Efforts of Kite and Juno (Kite, $48.53: Juno, $30.42)

Definition of Key Terms Used in This Report

Engineered Autologous T-cells (eACTS): These are T-cells that are removed from a patient…
Read more…

Juno Therapeutics: FDA Quickly Lifts Its Clinical Hold on ROCKET

The FDA has decided to lift the clinical hold on the ROCKET trial. Lifting the hold is not a great…
Read more…

Juno Therapeutics: Comments on Deaths in the ROCKET CAR-T Clinical Trial of JCAR-015(JUNO, $27.87)

Investment Perspective

I have been watching Kite and Juno for nearly two years and have occasionally written on the companies. I…
Read more…

CAR-T Companies-Kite (KITE, $55.09) and Juno (JUNO, $47.30): Is The Bloom Coming Off The Rose? Are Investor Expectations Unrealistic?

Introduction to This Thought Piece

Emerging biotechnology stocks obviously are very hard to value on an absolute basis because they usually…
Read more…